Clinical Pipeline
We are confidently progressing toward efficacy evaluations and commercial readiness. With diverse clinical studies planned, including wet and dry AMD as well as macular edemas, we welcome support from medical professionals and investors to bring Maculaser’s innovative solution to market.
Maculaser Enters Safety Trials
We are committed to delivering Maculaser as a safe and reliable option for healthcare professionals and a valuable investment opportunity. If you would like more information or are interested in being a part of this phase, please reach out to us.
Retina Platform Clinical Pipeline
